Airengy Tech: Does the Poland Financing Really Leave Enough Capital Headroom?
At first glance, Poland looks well funded: Airengy ended 2025 with NIS 44.8 million of cash and deposits, and then signed a EUR 9.3 million supplemental facility. The problem is that the financing stack is really an expensive bridge, and part of the apparent cushion leans on a NIS 50 million private placement that had still not largely turned into cash.
What This Follow-Up Is Testing
The main article argued that Airengy's pivot has already moved beyond narrative and into transactions, partners, and financing. This follow-up isolates the most practical question inside the Poland move: how much real capital room is left once the loan structure, the covenant definitions, and the still-uncollected equity are separated from each other.
The comfortable read tends to bundle three different layers as if they were the same cushion. At the end of 2025 the company had NIS 44.759 million of cash, cash equivalents, and deposits. On March 16, 2026 it signed EUR 9.3 million of supplemental financing. And in the background there is a NIS 50 million private placement approved in December 2025. Those are not the same type of capital. The first sits on the balance sheet already. The second is expensive bridge debt. The third is an irrevocable commitment that had still not mostly become cash. By the report date, only 57,143 shares had actually been exercised for total proceeds of NIS 200 thousand.
There is also a very fast regime change here. The 2025 base still looks like a company with no material credit on the balance sheet and no committed short-term bank lines, alongside management's assessment that it would not need additional financing over the coming year. Note 34 and the March immediate report show how quickly Poland then pulls reportable credit, security packages, financial covenants, and a revenue-linked payment mechanism into the picture. That is not an accounting contradiction. It is evidence that Poland moves the company from a cash-balance regime into a covenant regime.
The right framing here is all-in cash flexibility, meaning how much real capital freedom is left after the equity requirement, financing carry, amortization schedule, and covenant package are brought into one picture. Under that frame, the thesis is sharp: the Poland financing is enough to open stage 1, but the capital headroom looks wider than it really is because part of the cushion depends on a private placement that has not yet been collected, while the debt itself is priced like bridge financing rather than final project debt.
The Headroom Looks Wide Because It Mixes Cash, Bridge Debt, And Equity Not Yet Collected
The annual report's financing section initially feels comfortable. Working capital at December 31, 2025 stood at NIS 41.471 million, and the company had NIS 44.759 million of cash, cash equivalents, and short- and long-term deposits. Equity attributable to shareholders was still positive at NIS 43.071 million. Those are not weak starting numbers for a small company entering its first infrastructure-style acquisition outside Israel.
But this is where the definition layer matters. In the Poland financing agreement, the key equity covenant does not rely only on equity attributable to shareholders. It also adds the guaranteed share consideration from the December 2025 private placement, NIS 50 million. That is why the company presents covenant equity of NIS 93 million, versus reported equity attributable to shareholders of NIS 43.071 million in the year-end financial statements. Put differently, almost the entire jump from roughly NIS 43 million to roughly NIS 93 million comes from money the company expects to receive, not money that had already reached the balance sheet by the report date.
The private placement did not disappear. It simply had not been largely collected yet. Under section 34.4, investors committed to buy 14,285,714 shares at NIS 3.5 per share, by December 31, 2026, and delivered checks with the same maturity date. But by the report date the company had already disclosed that only NIS 200 thousand had actually been received. That makes it more accurate to read the NIS 50 million as contractual bridge equity, not as cash that was already freely deployable.
There is an important nuance here. Even without the private placement, equity attributable to shareholders at the end of 2025 was still slightly above the base covenant floor of NIS 40 million. So the placement does not create compliance from zero. What it does is inflate the safety margin dramatically. That is a critical distinction. It says the company did not enter the transaction on the edge of immediate breach, but it also did not enter it with a truly wide capital cushion once operating losses, the Italy project, Green-Go, and the later Poland stages are kept in view.
That gap becomes more visible in the second covenant. The agreement says the equity-to-balance-sheet ratio may not fall below 20% for two consecutive quarters, and the immediate report presents that ratio at 88% as of December 31, 2025. But that number is based on updated estimates that are neither reviewed nor audited, so the reader is not given a full bridge between the audited year-end balance sheet and the exact denominator used for that ratio. That is not proof that the ratio is weak. It is a reminder that part of the headroom presented to the lender rests on an estimated basis that differs from the audited basis the equity investor sees in the annual report.
This Is A Bridge Loan With A Double Price Tag
The second point that is easy to miss is that the EUR 9.3 million facility is not the same thing as the stage 1 purchase price. The binding acquisition price for stage 1 is EUR 10.373 million. Of that, the main facility is EUR 8.3 million or up to 80% of the stage 1 purchase price, whichever is lower. On top of that there is a EUR 1 million DDTL facility intended to fund interest and fees. The company must also invest from its own equity at least 20% of the stage 1 acquisition cost.
The practical meaning is straightforward. Even before stages 2 and 3, not all of the EUR 9.3 million goes into the asset purchase itself. EUR 1 million is earmarked from the outset for financing carry and fees, and the company still has to supply its own equity. So the cleaner way to read this agreement is as bridge financing that opens the deal, not as a closed financing package for the full capital structure.
| Item | What was agreed | Why it matters |
|---|---|---|
| Stage 1 price | EUR 10.373 million | This is the only fully binding acquisition already closed in structure |
| Main facility | EUR 8.3 million or up to 80% of stage 1 price | The debt covers most, but not all, of the first stage |
| DDTL facility | EUR 1 million | Part of the financing is earmarked for interest and fees rather than for the asset |
| Minimum equity | At least 20% of stage 1 cost | The company must bring its own capital from day one |
| Principal amortization | 40% within 18 months from stage 1 completion, 60% within 30 months | That is short for project debt, which is why this behaves like a bridge |
| Future senior financing | If it closes, part of the current loan is repaid already at first draw | The deal still assumes another financing layer later on |
This connects directly to section 1.5 of the immediate report. The company itself said it intends to finance the portfolio through equity, the supplemental loan, senior bank debt, and potentially institutional equity partners at the portfolio or holding-company level. So the question is not whether one source of funding was found. The question is how many layers remain open. The answer is more than one.
The 12% Revenue Payment Already Pulls The Lender Into The Upside
If the story stopped at 7% to 8% interest, this could still be read as expensive but ordinary debt. That is not the structure here. In addition to interest and fees, the lender is entitled to 12% of project revenue in 2028 and 2029, paid in four equal half-yearly installments. And if by June 30, 2027 the total project capacity is below 34 MW, that percentage rises according to the ratio between 34 MW and the actual operating capacity.
This is a particularly sharp point because the portfolio the company disclosed is described as having expected capacity of about 33.3 MW. In other words, on the face of the disclosure itself, the 34 MW threshold sits slightly above the headline capacity of the entire transaction. Actual operating capacity by the test date may end up higher, and the 33.3 MW figure may be a rounded presentation number. But based on the documents currently disclosed, the simplest conclusion is that the 12% is not obviously a hard ceiling. It is a base rate that can move upward if the realized capacity does not clear the threshold set in the agreement.
The deferral mechanism makes the same point from another angle. The company may defer those revenue-based payments for up to 12 months, but only by paying additional interest and a fee. So if 2028 and 2029 turn out to be tighter years than the current narrative suggests, the cost of capital does not disappear. It simply rolls forward at a higher price.
Alongside that sits a third covenant layer, one that is more operational. The company committed to separate semiannual EBITDA tests for the stage 1 companies and for the stage 2 and 3 companies. By the end of 2026 the minimum is EUR 175 thousand for the stage 1 companies and EUR 20 thousand for the stage 2 and 3 companies. By June 2027 that rises to EUR 240 thousand and EUR 200 thousand respectively. And if senior financing closes by December 31, 2026 and its covenant package is considered market-standard, the Project EBITDA covenant is replaced by the senior financing covenants. In plain terms, the current loan demands two fast proofs from the company: to secure senior financing, and to show that the projects are already moving toward EBITDA delivery even before the long-term capital structure is fully settled.
To that one has to add the collateral and default package. The lender receives security over company shares and group-company shares in the project companies, as well as security over the stage 1 project assets. There is also cross-default if another financial debt above EUR 250 thousand is accelerated. That means capital headroom is not just about how much money is left. It is also about how much room for maneuver remains if one of the axes slips.
Bottom Line
Does the Poland financing leave Airengy with enough capital headroom? Yes, but not in the quality the first read suggests. At the end of 2025 the company had enough audited equity to clear the NIS 40 million floor, and it also had NIS 44.759 million of cash and deposits. This is not a case of a company entering the deal with no air left. But it is also not a wide and clean capital cushion. A large part of the comfort presented to the lender depends on NIS 50 million from a private placement that had still not largely been collected, while the debt that was signed is not plain debt. It is bridge financing with interest, fees, revenue participation, relatively short amortization, and an explicit expectation of senior financing later on.
The right reading, then, is that Poland opened with enough room to start, not with a capital structure that can already be treated as finished. For that room to become truly sufficient, four things need to happen without much slippage: stage 1 has to close and move into orderly operation, a senior financing layer or equity partners have to come in on workable terms, the private-placement consideration has to turn into real cash rather than remain a deferred check, and stages 2 and 3 have to progress so that the 12% mechanism does not start stepping up before the full portfolio is operating. Until then, Poland looks less like a fully funded acquisition and more like a transaction opened with expensive bridge capital and not much room for error.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.